Skip to content

Glaukos GKOS Research And Development In Process Expense

Discontinued — last reported Q2 '24

Research And Development In Process Expense at other companies

Roivant Sciences logo
Roivant SciencesROIV
$0
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$0
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$101.9M+728%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$0
Natera, Inc. logo
Natera, Inc.NTRA
$2.68M+15.3%
3M logo
3MMMM
$308M+8.1%

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept gkos:ResearchAndDevelopmentInProcessExpense.

The official record: Glaukos’s 10-Q, filed August 4, 2025, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's research and development in process expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's research and development in process expense?
Glaukos (GKOS) reported research and development in process expense of $2.5M in Q2 2024.
How has Glaukos's research and development in process expense changed year-over-year?
Glaukos's research and development in process expense decreased by 16.7% year-over-year, from $3M to $2.5M.
What does research and development in process expense mean?
Costs related to acquiring or developing research projects that are not yet finished products.
How do you interpret research and development in process expense?
High levels of this expense indicate active inorganic growth strategies through acquisitions of early-stage technology.
How does research and development in process expense compare across companies?
Specific to companies that grow through M&A; peers often report this as a non-recurring item.